Fennec Pharmaceuticals Inc (FENC) - שווי פעילות לרווח לפני ריבית, מסים ופחת

The EV/EBITDA price action for Fennec Pharmaceuticals (FENC) on the GURU.Markets platform is 0.00, driven by high sales profitability of the orphan drug and efficient digital management. Fennec Pharmaceuticals (FENC) relies on contract manufacturing via Pedmark without maintaining its own facilities, while the stability of its market position is ensured by a narrow focus on hearing protection for children undergoing cancer treatment.

This indicator compares the total enterprise value, including net debt, with its operational profitability before depreciation and taxes. By analyzing the EV/EBITDA chart, an investor assesses the extent to which market expectations align with actual cash flow. For Fennec Pharmaceuticals (FENC), this calculation is critical, as the monopoly status of the drug Pedmark must convert into sustainable profit growth. Low values confirm the asset is undervalued given its patent-protected market positions.